88 related articles for article (PubMed ID: 12496865)
1. The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells.
Sepp-Lorenzino L; Balog A; Su DS; Meng D; Timaul N; Scher HI; Danishefsky SJ; Rosen N
Prostate Cancer Prostatic Dis; 1999 Jan; 2(1):41-52. PubMed ID: 12496865
[TBL] [Abstract][Full Text] [Related]
2. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
Kamath K; Jordan MA
Cancer Res; 2003 Sep; 63(18):6026-31. PubMed ID: 14522931
[TBL] [Abstract][Full Text] [Related]
3. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization.
Feyen F; Cachoux F; Gertsch J; Wartmann M; Altmann KH
Acc Chem Res; 2008 Jan; 41(1):21-31. PubMed ID: 18159935
[TBL] [Abstract][Full Text] [Related]
4. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag DM; McQueney PA; Zhu J; Hensens O; Koupal L; Liesch J; Goetz M; Lazarides E; Woods CM
Cancer Res; 1995 Jun; 55(11):2325-33. PubMed ID: 7757983
[TBL] [Abstract][Full Text] [Related]
5. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
Mooberry SL; Tien G; Hernandez AH; Plubrukarn A; Davidson BS
Cancer Res; 1999 Feb; 59(3):653-60. PubMed ID: 9973214
[TBL] [Abstract][Full Text] [Related]
6. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
Hoffmann J; Vitale I; Buchmann B; Galluzzi L; Schwede W; Senovilla L; Skuballa W; Vivet S; Lichtner RB; Vicencio JM; Panaretakis T; Siemeister G; Lage H; Nanty L; Hammer S; Mittelstaedt K; Winsel S; Eschenbrenner J; Castedo M; Demarche C; Klar U; Kroemer G
Cancer Res; 2008 Jul; 68(13):5301-8. PubMed ID: 18593931
[TBL] [Abstract][Full Text] [Related]
7. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
[TBL] [Abstract][Full Text] [Related]
8. Activity of epothilones.
Kolman A
Curr Opin Investig Drugs; 2005 Jun; 6(6):616-22. PubMed ID: 15988913
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
10. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
[TBL] [Abstract][Full Text] [Related]
11. Gene expression and mitotic exit induced by microtubule-stabilizing drugs.
Chen JG; Yang CP; Cammer M; Horwitz SB
Cancer Res; 2003 Nov; 63(22):7891-9. PubMed ID: 14633718
[TBL] [Abstract][Full Text] [Related]
12. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
Chen JG; Horwitz SB
Cancer Res; 2002 Apr; 62(7):1935-8. PubMed ID: 11929805
[TBL] [Abstract][Full Text] [Related]
13. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
14. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
Cortes J; Baselga J
Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
[TBL] [Abstract][Full Text] [Related]
15. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.
Tinley TL; Randall-Hlubek DA; Leal RM; Jackson EM; Cessac JW; Quada JC; Hemscheidt TK; Mooberry SL
Cancer Res; 2003 Jun; 63(12):3211-20. PubMed ID: 12810650
[TBL] [Abstract][Full Text] [Related]
16. Epothilones: mechanism of action and biologic activity.
Goodin S; Kane MP; Rubin EH
J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
[TBL] [Abstract][Full Text] [Related]
17. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).
Kowalski RJ; Giannakakou P; Hamel E
J Biol Chem; 1997 Jan; 272(4):2534-41. PubMed ID: 8999970
[TBL] [Abstract][Full Text] [Related]
18. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.
Sepp-Lorenzino L; Tjaden G; Moasser MM; Timaul N; Ma Z; Kohl NE; Gibbs JB; Oliff A; Rosen N; Scher HI
Prostate Cancer Prostatic Dis; 2001; 4(1):33-43. PubMed ID: 12497061
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
Chou TC; Dong H; Zhang X; Tong WP; Danishefsky SJ
Cancer Res; 2005 Oct; 65(20):9445-54. PubMed ID: 16230408
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts.
Newman RA; Yang J; Raymond M; Finlay V; Cabral F; Vourloumis D; Stephens LC; Troncoso P; Wu X; Logothetis CJ; Nicolaou KC; Navone NM
Cancer Chemother Pharmacol; 2001 Oct; 48(4):319-26. PubMed ID: 11710633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
